Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease.
- Donath MY Clinic of Endocrinology, Diabetes and Metabolism and Department of Biomedicine, University of Basel, Basel, Switzerland.
- Meier DT Clinic of Endocrinology, Diabetes and Metabolism and Department of Biomedicine, University of Basel, Basel, Switzerland.
- Böni-Schnetzler M Clinic of Endocrinology, Diabetes and Metabolism and Department of Biomedicine, University of Basel, Basel, Switzerland.
- 2019-05-26
Published in:
- Endocrine reviews. - 2019
English
The role of chronic inflammation in the pathogenesis of type 2 diabetes mellitus and associated complications is now well established. Therapeutic interventions counteracting metabolic inflammation improve insulin secretion and action and glucose control and may prevent long-term complications. Thus, a number of anti-inflammatory drugs approved for the treatment of other inflammatory conditions are evaluated in patients with metabolic syndrome. Most advanced are clinical studies with IL-1 antagonists showing improved β-cell function and glycemia and prevention of cardiovascular diseases and heart failure. However, alternative anti-inflammatory treatments, alone or in combinations, may turn out to be more effective, depending on genetic predispositions, duration, and manifestation of the disease. Thus, there is a great need for comprehensive and well-designed clinical studies to implement anti-inflammatory drugs in the treatment of patients with metabolic syndrome and its associated conditions.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1210/er.2019-00002
- PMID 31127805
- Persistent URL
- https://folia.unifr.ch/global/documents/183278
Statistics
Document views: 26
File downloads:
- fulltext.pdf: 0